BRAF and cancer: Small-molecule inhibitors of BRAF and its downstream-target MEK have already been approved for other BRAF-driven cancer types, such as melanoma [14] and have been shown to effectively inhibit glioma growth both in preclinical models [5, 9, 22, 36] and small patient cohorts [7, 17, 21].